Our observation that MDMX and MDM2 signaling pathways are different in TNBC and ERα+ breast cells has set the stage for suggesting the use of these biomarkers to more accurately define the nature of breast cancer subtypes. The gene discussed is ESR1; the disease is breast cancer.